Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension
Stuart Isaacson, Steven Vernino, Adam Ziemann, Gerald J Rowse, Uwa Kalu, William B White, Stuart Isaacson, Steven Vernino, Adam Ziemann, Gerald J Rowse, Uwa Kalu, William B White
Abstract
The long-term safety of droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Parkinson disease, pure autonomic failure, multiple system atrophy, or nondiabetic autonomic neuropathy was evaluated in a phase 3, multinational, open-label study in patients who previously participated in a double-blind, placebo-controlled clinical trial of droxidopa. A total of 350 patients received droxidopa 100 to 600 mg three times daily. Mean duration of droxidopa exposure was 363 days (range, 2-1133 days). Rates of serious adverse events (AEs), cardiac-related AEs, and supine hypertension were 24%, 5%, and 5%, respectively. Most AEs, including those of a cardiovascular nature, were not attributed by investigators to droxidopa. In this large cohort of patients with neurogenic orthostatic hypotension, droxidopa was well tolerated during long-term use.
Keywords: Supine hypertension.
Copyright © 2016 The Author. Published by Elsevier Inc. All rights reserved.
Source: PubMed